Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 10/20 | 0.39 |
| ▸ | BCHE | P06276 | 5/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.34 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.34 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30666539 | 1.00 | NOS3 (0.39) | NOS3NOS1NOS2ACHEBCHE | |
| SCHEMBL30666860 | 0.98 | NOS3 (0.38) | NOS3NOS1NOS2ACHEBCHE | |
| SCHEMBL827623 | 0.96 | GRM4 (0.39) | NOS3NOS1NOS2ACHEBCHE | |
| SCHEMBL29223369 | 0.78 | NR4A2 (0.60) | ACHEBCHEGRIN1GRIN2ACHRM1 | |
| SCHEMBL28217559 | 0.77 | GRM4 (0.47) | NOS3NOS1NOS2ACHEBCHE | |
| SCHEMBL795349 | 0.76 | NOS3 (0.44) | NOS3NOS1NOS2ACHEBCHE | |
| SCHEMBL24283716 | 0.74 | NOS3 (0.42) | NOS3NOS1NOS2ACHEBCHE | |
| SCHEMBL2087614 | 0.74 | NOS3 (0.48) | NOS3NOS1NOS2ACHEBCHE | |
| SCHEMBL22270533 | 0.74 | NOS3 (0.39) | NOS3NOS1NOS2ACHEBCHE | |
| SCHEMBL2624112 | 0.74 | BCL2L1 (0.42) | NOS3NOS1NOS2ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522595-B2 | Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | VERNALIS (R&D) LTD (GB) | 2024-05-09 | — | — | US | disclosed |
| EP-4277892-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2023-11-22 | — | — | EP | disclosed |
| CN-116940552-A | Spirocyclic hexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors | 法国施维雅药厂 | 2023-10-24 | — | — | CN | disclosed |
| WO-2022152705-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2022-07-21 | — | — | WO | disclosed |
| US-20220106305-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. | 2022-04-07 | — | — | US | disclosed |
| EP-3921316-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | Biogen MA Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
| WO-2020163193-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20180072757-A1 | Novel Heterocyclic Derivatives as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2018-03-15 | — | — | US | disclosed |
| US-7834016-B2 | Inhibitors of the interaction between MDM2 and p53 | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-16 | — | — | US | disclosed |
| EP-1809622-B1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-21 | — | — | EP | disclosed |
| US-20080039472-A1 | Inhibitors of the Interaction Between Mdm2 and P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
| EP-1809622-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006032631-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-30 | — | — | WO | disclosed |
| EP-0395244-B1 | Pyridine derivatives | WYETH JOHN & BROTHER LTD (GB) | 1997-02-19 | — | — | EP | disclosed |
| WO-1996037473-A1 | SUBSTITUTED 2,3-CYCLOALKENOPYRIDINES, PROCESS FOR PREPARING THE SAME, AGENTS CONTAINING THE SAME AND THEIR USE AS PESTICIDES AND FUNGICIDES | HOECHST SCHERING AGREVO GMBH (DE) | 1996-11-28 | — | — | WO | disclosed |
| US-5194439-A | 5-HT Agonists or Antagonists, Nervous System Disorders, Hypotensive Agents | JOHN WYETH & BROTHER LIMITED (GB) | 1993-03-16 | — | — | US | disclosed |
| US-5075303-A | Central nervous system disorders | JOHN WYETH & BROTHER LIMITED (GB) | 1991-12-24 | — | — | US | disclosed |
| EP-0395244-A1 | Pyridine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1990-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BAX, BCL2A1 | NOS3 2023/4885NOS1 2458/4885NOS2 2680/4885 |
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | NOS3 3434/4885NOS1 3631/4885NOS2 3796/4885 |
| US-20220106305-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | ENGASE, UGGT1, MGAT3 | NOS3 3467/4885NOS1 3701/4885NOS2 3337/4885 |
| US-20080039472-A1 | Inhibitors of the Interaction Between Mdm2 and P53 | TP53, MDM2, TP53BP1 | NOS3 2353/4885NOS1 2019/4885NOS2 2767/4885 |
| US-20180072757-A1 | Novel Heterocyclic Derivatives as Modulators of Kinase Activity | CDK2, MAP4K3, MAP4K2 | NOS3 1273/4885NOS1 1615/4885NOS2 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.